Dimebon Does Not Ameliorate Pathological Changes Caused by Expression of Truncated (1–120) Human Alpha-Synuclein in Dopaminergic Neurons of Transgenic Mice

BACKGROUND: Recent clinical studies have demonstrated that dimebon, a drug originally designed and used as a non-selective antihistamine, ameliorates symptoms and delays progress of mild to moderate forms of Alzheimer's and Huntington's diseases. Although the mechanism of dimebon action on...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Shelkovnikova, Tatyana A., Ustyugov, Alexey A., Millership, Steven, Peters, Owen, Anichtchik, Oleg, Spillantini, Maria Grazia, Buchman, Vladimir L., Bachurin, Sergey O., Ninkina, Natalia N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: S. Karger AG 2011
Gaiak:
Original Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186720/
https://ncbi.nlm.nih.gov/pubmed/21576917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000324989
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak